GS Investments Inc. Decreases Stock Position in Stryker Corporation $SYK

GS Investments Inc. cut its stake in Stryker Corporation (NYSE:SYK) by 22.2% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 11,685 shares of the medical technology company’s stock after selling 3,330 shares during the period. Stryker comprises about 2.2% of GS Investments Inc.’s holdings, making the stock its 13th largest holding. GS Investments Inc.’s holdings in Stryker were worth $4,107,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Malaga Cove Capital LLC purchased a new position in Stryker in the fourth quarter valued at $237,000. Integrity Advisory Solutions LLC boosted its holdings in Stryker by 11.5% in the fourth quarter. Integrity Advisory Solutions LLC now owns 1,279 shares of the medical technology company’s stock valued at $450,000 after purchasing an additional 132 shares during the period. Collaborative Wealth Managment Inc. purchased a new position in Stryker in the fourth quarter valued at $268,000. Goepper Burkhardt LLC boosted its holdings in Stryker by 4.5% in the fourth quarter. Goepper Burkhardt LLC now owns 2,037 shares of the medical technology company’s stock valued at $716,000 after purchasing an additional 87 shares during the period. Finally, Cary Street Partners Investment Advisory LLC boosted its holdings in Stryker by 4.6% in the fourth quarter. Cary Street Partners Investment Advisory LLC now owns 2,435 shares of the medical technology company’s stock valued at $856,000 after purchasing an additional 108 shares during the period. 77.09% of the stock is currently owned by hedge funds and other institutional investors.

Stryker Stock Down 1.1%

Stryker stock opened at $313.08 on Wednesday. Stryker Corporation has a 1-year low of $281.00 and a 1-year high of $404.87. The company has a debt-to-equity ratio of 0.62, a current ratio of 2.11 and a quick ratio of 1.25. The stock has a market cap of $120.02 billion, a PE ratio of 36.24, a P/E/G ratio of 1.99 and a beta of 0.80. The stock’s fifty day moving average is $324.33 and its two-hundred day moving average is $349.12.

Stryker (NYSE:SYK) last posted its quarterly earnings results on Thursday, April 30th. The medical technology company reported $2.60 earnings per share for the quarter, missing analysts’ consensus estimates of $2.98 by ($0.38). Stryker had a net margin of 13.20% and a return on equity of 23.42%. The business had revenue of $6.02 billion during the quarter, compared to analyst estimates of $6.34 billion. During the same quarter in the prior year, the business earned $2.84 earnings per share. The firm’s quarterly revenue was up 2.6% on a year-over-year basis. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. On average, sell-side analysts expect that Stryker Corporation will post 14.98 EPS for the current fiscal year.

Stryker Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, July 31st. Stockholders of record on Tuesday, June 30th will be given a dividend of $0.88 per share. The ex-dividend date is Tuesday, June 30th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.1%. Stryker’s payout ratio is 40.74%.

Insider Activity at Stryker

In other news, VP M Kathryn Fink sold 3,500 shares of Stryker stock in a transaction dated Monday, May 11th. The stock was sold at an average price of $283.45, for a total transaction of $992,075.00. Following the sale, the vice president owned 177 shares in the company, valued at approximately $50,170.65. The trade was a 95.19% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 4.60% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on SYK shares. Wells Fargo & Company decreased their target price on Stryker from $456.00 to $418.00 and set an “overweight” rating for the company in a report on Friday, May 1st. Robert W. Baird set a $385.00 target price on Stryker in a report on Friday, May 1st. The Goldman Sachs Group restated a “neutral” rating and issued a $361.00 price target on shares of Stryker in a research note on Friday, May 1st. BTIG Research cut their price target on Stryker from $397.00 to $379.00 and set a “buy” rating on the stock in a research note on Friday, May 1st. Finally, Wall Street Zen cut Stryker from a “buy” rating to a “hold” rating in a research note on Saturday, May 16th. Sixteen analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $395.48.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.